David McMillan, PhD

ProfessorDavid McMillan, PhD

Durham Research Center 3050
985800 University of Nebraska Medical Center
Omaha, NE 68198-5800

Email: David McMillan

YouTubeDr. McMillan in his own words.

In the News:

E-Learning Awards announced
UNMC Today | December 1, 2016

Research Interests
Representative Publications
Dr. McMillan's biographical information

Research Interests

My general area of research interest is in mechanisms of toxicity of drugs and environmental chemicals. More specifically, I am interested in the mechanism underlying pro-oxidant drug-induced hemolytic anemia and in the metabolism and toxicity of the environmental contaminant, trichloroethylene.

In regards to hemolytic anemia, I have worked to understand how redox-active metabolites of certain drugs cause oxidative damage within erythrocytes and how this damage commits the red cells to premature sequestration and phagocytosis by macrophages in the spleen. This toxicity is especially severe in patients with a genetic deficiency in erythrocytic glucose-6-phosphate dehydrogenase (G6PD) activity; these individuals are unable to maintain adequate levels of NADPH in response to oxidative stress. Certain drugs, such as the antimalarial agent, primaquine, are contraindicated in G6PD-deficiency, and part of my research has been directed towards the rational re-design of this drug so that it can be used safely in these patients.

In regards to education, I am interested in developing innovative web-based teaching methods in pharmacology that can be customized to fit the needs of different types of students who are obtaining professional degrees in the biomedical sciences. To provide a mechanism for this effort, I am participating in UNMC’s Instructional Technology Scholars Program. My long-range plans in this program are to develop an on-line pharmacology course for physical therapy students and evaluate its effectiveness using current qualitative methodology.

Representative Publications

  1. McMillan JM and McMillan DC. (2006). S-Adenosylmethionine but not glutathione protects against galactosamine-induced cytotoxicity in rat hepatocyte cultures. Toxicology 22, 175-184.  PMID 16564122.
  2. Bronley-DeLancey AY, McMillan DC, McMillan JM, Jollow DJ, Mohr LC and Hoel, D.G. (2006). Application of cryopreserved human hepatocytes in trichloroethylene risk assessment: relative disposition of chloral hydrate to trichloroacetate and trichloroethanol. Environ. Health Perspect. 114, 1237-1242.  PMID 1688253
  3. Bowman ZS, Morrow JD, Jollow DJ and McMillan DC. (2005). Primaquine-induced hemolytic anemia: Role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5-hydroxyprimaquine. J. Pharmacol. Exp. Ther. 314,838-845.  PMID 15840764
  4. Bowman ZS, Jollow DJ and McMillan DC. (2005). Primaquine-induced hemolytic anemia: Role of splenic macrophages in the fate of 5-hydroxyprimaquine-treated rat erythrocytes. J. Pharmacol. Exp. Ther. 315, 980-986.  PMID 16099929
  5. McMillan DC, Powell CL, Bowman ZS, Morrow JD, and Jollow DJ. (2005). Lipids vs. proteins as major targets of pro-oxidant, direct-acting hemolytic agents. Toxicol. Sci. 8, 274-283.  PMID 16107547

Dr. McMillan's biographical information
Top of page